33.43

2.92% 0.95

Supernus Pharmaceuticals Inc (SUPN)

Overview News Price History Option Chain Financials Why SUPN Down? Discussions Forecast

Supernus Pharmaceuticals Inc stock is traded at $33.43, with a volume of 548.99K. It is up +2.92% in the last 24 hours and up +8.86% over the past month. Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Previous Close:

$32.48

Open:

$32.47

24h Volume:

548.99K

Relative Volume:

0.91

Market Cap:

$1.87B

Revenue:

$651.97M

Net Income/Loss:

$59.71M

P/E Ratio:

31.25

EPS:

1.0696

Net Cash Flow:

$172.03M

1W Performance:

+5.46%

1M Performance:

+8.86%

6M Performance:

-6.02%

1Y Performance:

+14.64%

1-Day Range:

$32.34

$33.74

1-Week Range:

$31.38

$33.74

52-Week Range:

$25.53

$40.28

Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile

Name

Supernus Pharmaceuticals Inc

Sector

Healthcare (1170)

Industry

Drug Manufacturers - Specialty & Generic (1)

Phone

301-838-2500

Address

9715 KEY WEST AVENUE, ROCKVILLE, MD

Employee

674

Twitter

@Supernus_Pharma

Next Earnings Date

2024-11-04

Latest SEC Filings

SUPN's Discussions on Twitter

Compare SUPN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SUPN Supernus Pharmaceuticals Inc	33.43	1.77B	651.97M	59.71M	172.03M	1.0696
HLN Haleon Plc Adr	10.80	48.39B	14.35B	1.85B	0	0.4023
ZTS Zoetis Inc	163.04	70.91B	9.29B	2.52B	2.28B	5.57
RDHL Redhill Biopharma Ltd Adr	1.85	3.54M	35.75M	11.57M	-26.25M	-3.8069
TAK Takeda Pharmaceutical Co Adr	14.11	45.20B	30.08B	710.16M	4.45B	0.2182
TEVA Teva Pharmaceutical Industries Ltd Adr	16.94	19.42B	16.54B	-1.64B	749.00M	-1.45

Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-19-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-06-25	Initiated	Cantor Fitzgerald	Overweight
Sep-11-24	Downgrade	Piper Sandler	Overweight → Neutral
Jan-03-23	Resumed	Jefferies	Buy
Dec-01-21	Resumed	Jefferies	Buy
Apr-13-21	Upgrade	Jefferies	Hold → Buy
Jun-16-20	Upgrade	Piper Sandler	Neutral → Overweight
Jun-15-20	Resumed	Jefferies	Hold
Nov-08-19	Downgrade	Berenberg	Buy → Hold
Nov-07-19	Downgrade	Stifel	Buy → Hold
Nov-06-19	Downgrade	Jefferies	Buy → Hold
Nov-12-18	Reiterated	B. Riley FBR	Buy
Jan-18-18	Reiterated	B. Riley FBR, Inc.	Buy
Dec-28-17	Reiterated	B. Riley FBR, Inc.	Buy
Dec-04-17	Upgrade	Janney	Neutral → Buy
Nov-08-17	Upgrade	Stifel	Hold → Buy
Oct-19-17	Initiated	FBR & Co.	Buy
Sep-19-17	Downgrade	Stifel	Buy → Hold
Jul-17-17	Downgrade	Piper Jaffray	Overweight → Neutral
Jul-14-17	Initiated	Janney	Neutral
Jun-01-17	Upgrade	Piper Jaffray	Neutral → Overweight
Jul-18-16	Downgrade	Northland Capital	Outperform → Market Perform
Jul-18-16	Downgrade	Piper Jaffray	Overweight → Neutral
Feb-08-16	Upgrade	Jefferies	Hold → Buy
Nov-05-15	Reiterated	Northland Capital	Outperform
Oct-28-15	Initiated	Northland Capital	Outperform

View All

Supernus Pharmaceuticals Inc Stock (SUPN) Latest News

May 15, 2025

The Manufacturers Life Insurance Company Sells 797 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World

May 15, 2025

May 14, 2025

Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock? - Nasdaq

May 14, 2025

May 13, 2025

Solid Earnings Reflect Supernus Pharmaceuticals' (NASDAQ:SUPN) Strength As A Business - Yahoo Finance

May 13, 2025

Supernus Pharmaceuticals (SUPN) to Release Quarterly Earnings on Wednesday - Defense World

May 13, 2025

May 12, 2025

SUPN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Supernus Pharmaceuticals, Inc. investment - ACCESS Newswire

May 12, 2025

May 10, 2025

Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by StockNews.com - Defense World

May 10, 2025

May 09, 2025

Supernus projects $600M-$630M revenue for 2025 with robust growth in core products - MSN

May 09, 2025

Lost Money on Supernus Pharmaceuticals, Inc. (SUPN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire

May 09, 2025

May 08, 2025

Stock Surge: Supernus Pharmaceuticals Inc (SUPN) Closes at 30.94, Marking a -4.59 Increase/Decrease - DWinneX

May 08, 2025

Levi & Korsinsky Reminds Supernus Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsSUPN - ACCESS Newswire

May 08, 2025

Supernus Pharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

May 08, 2025

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by First Trust Advisors LP - Defense World

May 08, 2025

May 07, 2025

SUPN STOCK ALERT: Levi & Korsinsky Notifies Supernus Pharmaceuticals, Inc. Investors of an Ongoing Investigation - ACCESS Newswire

May 07, 2025

Earnings call transcript: Supernus Q1 2025 earnings miss expectations By Investing.com - Investing.com Canada

May 07, 2025